MYOV Myovant Sciences Ltd.

6.09
-0.09  -1%
Previous Close 6.18
Open 6.18
Price To Book 6.84
Market Cap 545,801,792
Shares 89,622,626
Volume 49,757
Short Ratio 13.84
Av. Daily Volume 324,243

NewsSee all news

  1. Myovant Sciences' Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance

    Roivant's ownership interest in Myovant Sciences (approximately 46% of shares issued and outstanding) to be fully assumed by a new entity, Sumitomo Dainippon-Roivant Alliance, which will be wholly owned by Sumitomo

  2. Myovant Sciences to Participate in Upcoming September Investor Conferences

    BRISBANE, Calif. and BASEL, Switzerland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women's

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data 1Q 2020.
Relugolix - SPIRIT 1
Endometriosis-associated pain
Phase 3 completion of enrolment announced August 20, 2019 with data due 2Q 2020.
Relugolix - SPIRIT 2
Endometriosis-associated pain
Phase 3 data due 4Q 2019.
Relugolix - HERO
Advanced prostate cancer
NDA filing due 4Q 2019.
Relugolix - LIBERTY 1 and LIBERTY 2
Menstrual bleeding associated with uterine fibroids

Latest News

  1. Myovant Sciences' Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance

    Roivant's ownership interest in Myovant Sciences (approximately 46% of shares issued and outstanding) to be fully assumed by a new entity, Sumitomo Dainippon-Roivant Alliance, which will be wholly owned by Sumitomo

  2. Myovant Sciences to Participate in Upcoming September Investor Conferences

    BRISBANE, Calif. and BASEL, Switzerland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women's